Quick Answer
Revium Rx. reported Net Income of -$13.45 million for fiscal year 2025.
Revium Rx. — Key Financials by Year
| Metric | 2025 | 2024 |
|---|---|---|
| Net Income | -$13.45M | — |
| Diluted EPS | -$0.22 | — |
| Total Assets | $8.30M -59.1% |
$20.28M |
| Cash and Equivalents | $1.68M -48.7% |
$3.27M |
| Stockholders Equity | $6.88M -65.1% |
$19.71M |
| Shares Outstanding | 60.73M +0.0% |
60.73M |
- Revium Rx. reported Net Income of -$13.45 million for fiscal year 2025.
- Revium Rx. reported Diluted EPS of $0.22 per share (loss) for fiscal year 2025.
- Revium Rx. reported Total Assets of $8.30 million for fiscal year 2025.
- Revium Rx. showed a decrease of -59.1% in Total Assets compared to the prior fiscal year.
- Revium Rx. reported Cash and Equivalents of $1.68 million for fiscal year 2025.
- Revium Rx. showed a decrease of -48.7% in Cash and Equivalents compared to the prior fiscal year.
- Revium Rx. reported Stockholders Equity of $6.88 million for fiscal year 2025.
- Revium Rx. showed a decrease of -65.1% in Stockholders Equity compared to the prior fiscal year.
- Revium Rx. reported Shares Outstanding of 60.73 million shares for fiscal year 2025.
- Revium Rx. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: